EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

The ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure

Anggoro Budi Hartopo iD, Arinal Chairul Achyar iD, Hendry Purnasidha Bagaswoto iD, Firandi Saputra iD, Hasanah Mumpuni, Dyah Adhi Kusumastuti iD, Teguh Triyono iD, Usi Sukorini iD, Metalia Puspitasari, Budi Yuli Setianto iD, Mohammad Saifur Rohman iD, Muhammad Anshory iD und 8 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15191 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Anggoro Budi Hartopo und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogya…. Hauptthemen laut MEDLINE: Adrenomedullin, Antibodies, Monoclonal, Humanized, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aimed to conduct a phase 2 proof-of-concept and safety study to evaluate the effect of ENIBARCIMAB (EN), a non-neutralizing humanized monoclonal antibody targeting the N-terminus of adrenomedullin (ADM), administered immediately after stabilization with standard of care (SoC) treatment, in patients hospitalized for acute heart failure (AHF). Methods and results This prospective, open-label, controlled, interventional, multicenter, dose-escalation study was conducted at two cardiology sites in Indonesia. Patients were divided into two interventional groups sequentially receiving 0.5 mg/kg (SoC + EN 0.5 mg/kg, n = 10; first cohort) and 2 mg/kg (SoC + EN 2 mg/kg, n = 10; second cohort) of EN via 1-h intravenous (IV) infusion within 48 h after admission for AHF. The control group (n = 10) was treated with SoC therapy for AHF therapy. All patients were monitored continuously within 24 h post-infusion and subsequent daily until discharge. Treatment-related serious adverse events (SAEs) were recorded during hospitalization and up to 90 days after discharge. Both EN dosages were well-tolerated, and no significant safety issues were identified during hospitalization and up to 90 days of follow up. SAEs occurred in 10% of patients in each EN group but were deemed not related to treatment. No significant differences in the occurrence of SAEs were found between the groups. Five deaths occurred: three (30%) in the control group as compared with two deaths (20%) in the SoC + EN 2 mg/kg group. EN led to a significant increase in plasma bio-ADM levels within 24 h post-infusion, with the SoC + 2 mg/kg group showing the highest increase. Within 1 h from IV EN infusion, SoC + EN 2 mg/kg compared with 0.5 mg/kg, resulted in a significant percentage reduction in systolic, diastolic blood pressure, and mean arterial pressure. However, it did not result in severe hypotension and the need for drug discontinuation.

Conclusions

In this pilot safety study of patients hospitalized for AHF, IV infusion of EN 0.5 and 2 mg/kg increased circulating plasma bio-ADM levels and was well-tolerated without treatment-related SAEs occurring during hospitalization and up to 90 days after discharge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdrenomedullinAntibodies, Monoclonal, HumanizedHeart FailureAgedFemaleHumansMaleMiddle AgedAcute DiseaseDose-Response Relationship, DrugFollow-Up StudiesInfusions, IntravenousProspective StudiesTreatment OutcomeProof of Concept Study

Stichwörter der Autor:innen

Acute heart failureBio‐adrenomedullinENIBARCIMABSafetyTolerability

Substanzen

AdrenomedullinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Cardiology and Vascular Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
  • Department of Clinical Pathology and Laboratory Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
  • Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar Hospital, Malang, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar Hospital, Malang, Indonesia.
  • Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Universitas Brawijaya Hospital, Malang, Indonesia.

ORCID-Profile: Anggoro Budi Hartopo, Arinal Chairul Achyar, Hendry Purnasidha Bagaswoto, Firandi Saputra, Dyah Adhi Kusumastuti, Teguh Triyono, Usi Sukorini, Budi Yuli Setianto, Mohammad Saifur Rohman, Muhammad Anshory, Yoga Waranugraha, Putri Annisa Kamila, Agustin Iskandar, Hani Susianti

Zitieren

APA

Hartopo, A. B., Achyar, A. C., Bagaswoto, H. P., Saputra, F., Mumpuni, H., Kusumastuti, D. A., Triyono, T., Sukorini, U., Puspitasari, M., Setianto, B. Y., Rohman, M. S., Anshory, M., Waranugraha, Y., Kamila, P. A., Iskandar, A., Susianti, H., Bergman, A., Knothe, C., Antonini, P., & Di Somma, S. (2025). The ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.15191

Vancouver

Hartopo AB, Achyar AC, Bagaswoto HP, Saputra F, Mumpuni H, Kusumastuti DA, et al. The ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure. ESC Heart Failure. 2025. doi:10.1002/ehf2.15191

BibTeX
@article{Hartopo2025,
  author = {Hartopo, Anggoro Budi and Achyar, Arinal Chairul and Bagaswoto, Hendry Purnasidha and Saputra, Firandi and Mumpuni, Hasanah and Kusumastuti, Dyah Adhi and Triyono, Teguh and Sukorini, Usi and Puspitasari, Metalia and Setianto, Budi Yuli and Rohman, Mohammad Saifur and Anshory, Muhammad and Waranugraha, Yoga and Kamila, Putri Annisa and Iskandar, Agustin and Susianti, Hani and Bergman, Andreas and Knothe, Claudia and Antonini, Paola and Di Somma, Salvatore},
  title = {The ADESTE Trial: A Phase 2 Study of Enibarcimab, a Monoclonal Antibody Targeting Adrenomedullin, in Acute Heart Failure},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15191}
}
Kostenlos starten →